Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986523 Monotherapy and Combinations in Advanced Solid Malignancies
NCT07223047Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Primary completion
- Oct 2028
- Countries
- 3
01
Overview
Phase 2, open-label trial of BMS-986523 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Adverse Events up to 3 years, Serious Adverse Events up to 3 years and 3 more. Started Nov 2025; status: recruiting.
02
Drugs
BMS-986523
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07223047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07223047.